About Celldex Therapeutics, Inc.
https://www.celldex.comCelldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer.
CEO
Anthony S. Marucci
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-02-11 | Reverse | 1:15 |
| 2008-03-10 | Reverse | 1:12 |
ETFs Holding This Stock
Summary
Showing Top 3 of 124
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Canaccord Genuity
Buy
HC Wainwright & Co.
Buy
Citigroup
Buy
UBS
Buy
Wells Fargo
Overweight
Morgan Stanley
Overweight
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
KYNAM CAPITAL MANAGEMENT, LP
Shares:6.1M
Value:$160.69M
WELLINGTON MANAGEMENT GROUP LLP
Shares:5.8M
Value:$152.77M
BLACKROCK, INC.
Shares:5.51M
Value:$145.03M
Summary
Showing Top 3 of 209
About Celldex Therapeutics, Inc.
https://www.celldex.comCelldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 ▼ | $73.62M ▲ | $-67.04M ▼ | 0% ▲ | $-1.01 ▼ | $-72.79M ▼ |
| Q2-2025 | $730K ▲ | $64.59M ▲ | $-56.6M ▼ | -7.75K% ▼ | $-0.85 ▼ | $-62.98M ▼ |
| Q1-2025 | $695K ▼ | $63.43M ▲ | $-53.8M ▼ | -7.74K% ▼ | $-0.81 ▼ | $-61.87M ▼ |
| Q4-2024 | $1.18M ▼ | $56.38M ▲ | $-47.09M ▼ | -4.01K% ▼ | $-0.71 ▼ | $-55.21M ▼ |
| Q3-2024 | $3.19M | $55.32M | $-42.12M | -1.32K% | $-0.64 | $-51.34M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $583.22M ▼ | $648.44M ▼ | $50.08M ▲ | $598.36M ▼ |
| Q2-2025 | $630.34M ▼ | $692.41M ▼ | $37M ▲ | $655.41M ▼ |
| Q1-2025 | $673.29M ▼ | $739.47M ▼ | $36.49M ▼ | $702.98M ▼ |
| Q4-2024 | $725.28M ▼ | $792.34M ▼ | $45.34M ▲ | $747M ▼ |
| Q3-2024 | $756M | $823.18M | $37.27M | $785.9M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-67.04M ▼ | $-48.63M ▼ | $60.85M ▲ | $774K ▲ | $12.99M ▲ | $-49.07M ▼ |
| Q2-2025 | $-56.6M ▼ | $-44.01M ▲ | $49.85M ▲ | $63K ▼ | $5.91M ▲ | $-44.73M ▲ |
| Q1-2025 | $-53.8M ▼ | $-54.37M ▼ | $42.95M ▲ | $202K ▼ | $-11.22M ▼ | $-54.64M ▼ |
| Q4-2024 | $-47.09M ▼ | $-32.48M ▲ | $24.05M ▼ | $386K ▼ | $-8.04M ▼ | $-33.23M ▲ |
| Q3-2024 | $-42.12M | $-55.34M | $47.76M | $1.24M | $-6.34M | $-54.72M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Grant | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Service | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Anthony S. Marucci
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-02-11 | Reverse | 1:15 |
| 2008-03-10 | Reverse | 1:12 |
ETFs Holding This Stock
Summary
Showing Top 3 of 124
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Canaccord Genuity
Buy
HC Wainwright & Co.
Buy
Citigroup
Buy
UBS
Buy
Wells Fargo
Overweight
Morgan Stanley
Overweight
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
KYNAM CAPITAL MANAGEMENT, LP
Shares:6.1M
Value:$160.69M
WELLINGTON MANAGEMENT GROUP LLP
Shares:5.8M
Value:$152.77M
BLACKROCK, INC.
Shares:5.51M
Value:$145.03M
Summary
Showing Top 3 of 209